Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 593Glioblastoma 573Glioma 298Central Nervous System Neoplasms 208Gliosarcoma 177Neuroblastoma 175Astrocytoma 174Oligodendroglioma 112Carcinoma, Non-Small-Cell Lung 92Medulloblastoma 80Breast Neoplasms 74Ependymoma 61Sarcoma 60Meningioma 60Neoplasm Metastasis 57Recurrence 56Melanoma 56Neoplasms 51Lung Neoplasms 48Neurofibromatosis 1 43Meningeal Carcinomatosis 40Osteosarcoma 39Pheochromocytoma 38Rhabdomyosarcoma 37Wilms Tumor 36Paraganglioma 35Lymphoma, Non-Hodgkin 32Neuroectodermal Tumors, Primitive, Peripheral 29Lymphoma 27Sarcoma, Ewing 26

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Vascular Neoplasms × CNS × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡